• Теги
    • избранные теги
    • Компании2027
      • Показать ещё
      • Показать ещё
      Страны / Регионы431
      • Показать ещё
      Международные организации36
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
23 марта, 17:59

AstraZeneca Stock Rising in '17: What's Working in its Favor?

Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.

21 марта, 22:19

Infinity Pharma Focuses on Cancer Drug: Competition Looms

We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

20 марта, 17:32

AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

17 марта, 16:42

AstraZeneca (AZN): Should Value Investors Pick this Stock?

Is AstraZeneca a great pick from the value investor's perspective right now? Read on to know more.

17 марта, 16:27

Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

Выбор редакции
16 марта, 17:46

Inovio (INO) Q4 Loss Wider than Expected; Shares Decline

Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.

Выбор редакции
15 марта, 22:47

AstraZeneca's Cancer Drug Lynparza Positive in Phase III

AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.

15 марта, 18:41

Fed Watching Can Be A Costly Distraction

Another hike in the federal funds rate on Wednesday appears all-but certain. Experts, prediction markets, and Fed officials themselves all indicate that the central bank is ready to raise target

15 марта, 08:03

Возможности привлечения передовых шведских технологий для перевооружения российской промышленности обсудили в Стокгольме

Перспективы взаимодействия в области деревянного домостроения и использования технологий переработки бытовых отходов, других шведских лучших практик и технологий обсуждались на переговорах первого заместителя Министра промышленности и торговли Российской Федерации Глеба Никитина со статс-секретарем, заместителем Министра торговли Швеции Оскаром Стенстрёмом и с сопредседателем Российско-Шведского Наблюдательного комитета по торговле и экономическому сотрудничеству, Министром по делам ЕС и торговли Швеции Анн Линде, которые состоялись при поддержке Торгового представительства России в Швеции. Стороны обсудили перспективы проведения заседания российско-шведского Делового Совета в рамках международной промышленной выставки «Иннопром 2017» 10-13 июля 2017 года в г. Екатеринбурге. Они подтвердили заинтересованность в том, чтобы встреча сопредседателей Российско-Шведского Наблюдательного комитета по торговле и экономическому развитию состоялась в текущем году. Кроме того, стороны договорились обсудить вопросы и проблемы, возникающие как у российских, так и у шведских компаний, осуществляющих свою деятельность на территории стран в рамках очередного заседания рабочей группы по инвестиционному сотрудничеству в Стокгольме 30 марта 2017 года. Глава российской делегации вручил Анн Линде приглашение провести встречу сопредседателей Наблюдательного комитета на полях Петербургского международного экономического форума в июне 2017 г. Кроме того, состоялась встреча с представителями крупных шведских компаний, работающих на российском рынке и заинтересованных в дальнейшем расширении своей деятельности (Volvo Trucks, Scania, AstraZeneca, ABB, SCA, IKEA, DeLaval), а также посещение производственной площадки компании Ericsson.

Выбор редакции
Выбор редакции
Выбор редакции
14 марта, 21:45

AstraZeneca drug reduces risks in ovarian cancer

Anglo-Swedish group seeks approval for its use as longer-term therapy for sufferers

13 марта, 16:06

Your Organization Wastes Time. Here’s How to Fix It.

A year into their jobs, how many employees still have the unbridled energy and enthusiasm that they brought with them to their first day on the job? How many still believe they can make a difference? Unproductive routines, corporate bureaucracy, and “administrivia” kill ambition and sap energy for far too many employees. That’s demoralizing for employees, and a waste for companies, which badly need the full energy and commitment of all their workers. Related Video Your Scarcest Resource Organizations waste too much time - see how Bain helps them manage it like money in this 10-minute video slide deck. To download a customizable version, visit the Visual Library. Save Share See More Videos > See More Videos > The novelty of any new job will wear off, but employees can remain energized and engaged if companies attack the true causes of organizational drag — all the practices, procedures, and structures that waste time and limit output — not just the symptoms. The symptoms may seem to be minor annoyances and inconveniences that could be wiped out without much effort — too much process, too many meetings, meaningless goals, and time wasted on work that no one will ever care about. But those symptoms stem from fundamental problems. Companies wind up in trouble and squander the time, talent, and energy of their workforce when they lose focus, spend money on things that don’t make a difference to employees or the future of the business, and use operating models that are out of whack. By attacking the root causes of organizational drag, companies can eliminate unnecessary work, reenergize the workforce and, at the same time, put the business on a better course. They can do this by following the three R’s: refocus on strategic priorities reset the budgets redesign the operating model Together, these initiatives can help remove the clutter and distraction that create drag. Refocus on Strategic Priorities The first step is to refocus the organization on the most important business units, customer segments, and geographies in which the company has a repeatable formula for growth and a “right to win.” Within business units, executives should eliminate any sources of profitless volume. Look closely, and you’ll find that most companies have stretched their brands and product portfolios to customers and markets in which they are undifferentiated and profits are weak. These proliferating operations lead to complexity, which contributes to drag as well as costs that rob resources from better and potentially more-profitable ideas. For example, large biopharma companies compete in many categories and tend to accumulate an array of follower positions. But that drags down shareholder returns. Recent analysis by Bain found that the biggest biopharma value creators are category leaders, and those that combine their category leadership with portfolio focus within their categories deliver annual total shareholder returns more than twice those of companies that are diversified followers. That’s why a growing number of biopharma firms have been selling or spinning off parts of their businesses, such as Novartis’s sale of its influenza vaccine business to CSL, Bristol-Myers Squibb’s sale of its diabetes division to AstraZeneca, and Biogen’s spin-off of its hemophilia business. Trimming a portfolio of drag creators is often an act of managerial courage. It’s most likely that top-line growth will suffer during the transition, but the result will be a more profitable portfolio that is geared for growth. Companies often use separations and carve-outs to surgically eliminate the slower-growing, less-profitable, or less strategically aligned parts of their business. But if companies do not also address the underlying factors that got the company to that spot in the first place, their performance will still fall short of internal and external expectations. Reset the Budgets How companies allocate money can contribute to organizational drag by keeping nonessential work going. But it is not easy to make the tough decisions to defund. We recommend zero-based budgeting and planning to make the choices clearer. This also helps get over the dilemma that companies often face when they are making cuts: Should they eliminate the work and then reduce the budgets that allowed these costs, or should they shrink the budgets to squeeze out the unnecessary work? While the former approach is friendlier from a change management perspective, we usually find that it leads to only incremental change. This is why we find a zero-based approach preferable. A zero-based budgeting and planning process using stretch targets challenges conventional thinking and brings forth bolder ideas. Companies with foresight will make this change before the market or an activist investor demands it. A simple example: Before 3G Capital used a zero-based system to clarify roles and objectives, eliminate layers, and standardize processes at Kraft Heinz, one manager reported that he struggled to keep pace with a flood of up to 300 emails and numerous unproductive meetings in a typical day. Now his inbox collects fewer than 40 daily emails, and meetings are more focused and efficient. Zero-basing can both reset the cost structure and keep out cost over time. Redesign the Operating Model Having streamlined the portfolio and reset budgets, it is important to redesign the operating model — that is, the way the company is organized to deliver on its strategy — to eliminate any unnecessary work or dysfunctional processes that bog things down. Thinking “customer-back” or “frontline-back” provides a powerful lens through which to eliminate work. Just ask: How does this activity help serve our customers better? Companies can also look for complexity and inefficiencies that are hidden in the seams of the organization — in cross-functional, cross-geographical, or cross-business unit activities, where no executive or team has a single point of accountability. Every organization has seams, and these are fruitful areas for optimization and redesign. Where inefficiencies are found in ongoing operations, companies should consider “leaning out,” centralization, or outsourcing. Organizations operate on formal and informal processes, and executives should seek out complexity and waste in both areas. Formal processes and systems enshrine ways of working, so it’s easier to attack them systematically. But hidden and informal factors that create organizational drag tend to get overlooked. These factors are often more behavioral — how the management team makes decisions, for example. Consider the remarkable turnaround at Ford. In 2006 then-new CEO Alan Mulally and his senior team not only set a new strategic path but also overhauled Ford’s operating model. The company moved from regional business units to a global functional model, setting the stage for more-efficient and effective operations, such as reducing the number of vehicle platforms. Governance and behaviors changed as well, as Mulally pushed for open debate and honesty about where problems were cropping up. He encouraged his team to simplify the ways they worked, eliminating ineffective meetings and liberating thousands of unproductive hours. Thanks to a new strategy and an operating model redesign, Ford returned to profitability without a bailout from the American taxpayer. Following these three steps can elevate a company’s performance potential by creating an environment in which individual energy and creativity are converted to productivity. That can initiate a virtuous cycle in which improved performance liberates cash and capital to fund new growth opportunities and reward talent, unlocking new levels of organizational performance. Employees working in this winning environment will find that the new-employee spirit can be sustained and that their work feeds their individual energy rather than destroying it.

Выбор редакции
10 марта, 20:52

Healthcare Giant's Profits Not As Large As They Appear

From yesterday’s research, analysts parsed 63 10-K filings and collected 8,240 data points. In total they made 1,379 forensic accounting adjustments with a dollar value of $200 billion. Analyst Cody Fincher found an unusual item yesterday in Astrazeneca PLC’s (AZN) 20-F.

10 марта, 15:51

How Incyte Stock Became a Bull Market Star for Biotech Investors

Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

Выбор редакции
09 марта, 18:55

Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

06 марта, 17:30

The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi